Sugi Predict

Sugi Predict / Compounds / SCHEMBL7977811

SCHEMBL7977811

SCHEMBL7977811

COCCOCCOCCCO

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ TSHR P16473 3/20 0.46
▸ MAPK1 P28482 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ CYP3A4 P08684 2/20 0.34
▸ CA2 P00918 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ GAA P10253 1/20 0.33
▸ CYP4F2 P78329 1/20 0.33
▸ CYP4A11 Q02928 1/20 0.33
▸ EPHX2 P34913 2/20 0.33
▸ ABCB11 O95342 1/20 0.30
▸ ADRA2B P18089 1/20 0.30
▸ OPRD1 P41143 1/20 0.30
▸ SCN5A Q14524 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20067015 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL20067012 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL1071488 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL2399487 1.00 — —
SCHEMBL20067010 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL20067038 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL20067013 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL20067014 1.00 MEN1 (0.46) MEN1KMT2ATHRBHTTMAPT
SCHEMBL31608767 0.97 MEN1 (0.44) MEN1KMT2ATHRBHTTMAPT
SCHEMBL8270048 0.95 MEN1 (0.54) MEN1KMT2ATHRBHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441716-B2 Compositions and methods for increasing muscle mass and oxidative metabolism THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-14 — — US disclosed
EP-3952849-B1 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM UNIV CALIFORNIA (US) 2024-09-18 — — EP disclosed
US-20230246239-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2023-08-03 — — US disclosed
US-20230246238-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2023-08-03 — — US disclosed
US-20230203498-A1 SINGLE-STRANDED OLIGONUCLEOTIDE NISSAN CHEMICAL CORPORATION (JP) 2023-06-29 — — US disclosed
US-20220162198-A1 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-05-26 — — US disclosed
EP-3952849-A2 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-16 — — EP disclosed
CN-113924085-A Compositions and methods for increasing muscle mass and oxidative metabolism 加利福尼亚大学董事会 2022-01-11 — — CN disclosed
WO-2020210521-A2 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-10-15 — — WO disclosed
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 — — US disclosed
CN-109722259-A The preparation method of aligning agent for liquid crystal, the forming method of liquid crystal orientation film and display element 捷恩智株式会社 2019-05-07 — — CN disclosed
US-20180108944-A1 GRAPHENE COMPOUND AND MANUFACTURING METHOD THEREOF, ELECTROLYTE, AND POWER STORAGE DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-04-19 — — US disclosed
US-8586681-B2 Multi-arm block copolymers as drug delivery vehicles NEKTAR THERAPEUTICS (US) 2013-11-19 — — US disclosed
US-20130144014-A1 MULTI-ARM BLOCK COPOLYMERS AS DRUG DELIVERY VEHICLES NEKTAR THERAPEUTICS (US) 2013-06-06 — — US disclosed
US-8338545-B2 Multi-arm block copolymers as drug delivery vehicles NEKTAR THERAPEUTICS (US) 2012-12-25 — — US disclosed
US-20120046422-A1 Multi-Arm Block Copolymers as Drug Delivery Vehicles NEKTAR THERAPEUTICS (US) 2012-02-23 — — US disclosed
EP-2333608-A1 COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD FOR PRODUCTION THEREOF, AND SOLID IMAGING ELEMENT FUJIFILM Corporation (JP) 2011-06-15 — — EP disclosed
US-6288061-B1 INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS WELFIDE CORPORATION (JP) 2001-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203498-A1 SINGLE-STRANDED OLIGONUCLEOTIDE RNASEH1, RNASEL, RNASE1 MEN1 3475/4885KMT2A 3435/4885THRB 2734/4885
US-12441716-B2 Compositions and methods for increasing muscle mass and oxidative metabolism CPT1B, GYS1, PYGM MEN1 4729/4885KMT2A 3175/4885THRB 1478/4885
US-20220162198-A1 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM CPT1B, GYS1, PYGM MEN1 4764/4885KMT2A 3365/4885THRB 1328/4885
US-20180108944-A1 GRAPHENE COMPOUND AND MANUFACTURING METHOD THEREOF, ELECTROLYTE, AND POWER STORAGE DEVICE ILK, GK, KCNH3 MEN1 4232/4885KMT2A 1311/4885THRB 4120/4885
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL MEN1 2317/4885KMT2A 1975/4885THRB 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.